These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 6206649)

  • 1. [Peptides--inhibitors of carboxycathepsin (peptidyl-dipeptidase A) and their role in clinical medicine].
    Orekhovich VN; Eliseeva IuE; Pavlikhina LV; Krit NA; Filatova MP
    Vopr Med Khim; 1984; 30(3):51-6. PubMed ID: 6206649
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of converting enzyme inhibitors on renin-angiotensin system in normal rats.
    Komori T; Takada T; Funae Y; Yamamoto K
    Osaka City Med J; 1984 Jun; 30(1):17-30. PubMed ID: 6096787
    [No Abstract]   [Full Text] [Related]  

  • 3. [Properties and action specificity of carboxycathepsin (peptidyl dipepsidase) from bovine kidneys].
    Eliseeva IuE; Orekhovich VN; Pavlikhina LV
    Vopr Med Khim; 1976; 22(1):81-9. PubMed ID: 193290
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The angiotensin I converting enzyme.
    Erdös EG
    Fed Proc; 1977 Apr; 36(5):1760-5. PubMed ID: 191298
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A comparison of inhibition of angiotensin I conversion by three converting enzyme inhibitors in rats.
    Takata Y; Di Nicolantonio R; Hutchinson JS
    Clin Exp Pharmacol Physiol Suppl; 1982; 7():129-34. PubMed ID: 6183035
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Role of peptidases in regulating vascular tonus].
    Orekhovich VN; Eliseeva IuE; Pavlikhina LV
    Vestn Akad Med Nauk SSSR; 1982; (9):34-8. PubMed ID: 6128841
    [No Abstract]   [Full Text] [Related]  

  • 7. Angiotensin-dependent hypertension--potential pitfalls in definition.
    Williams GH
    N Engl J Med; 1977 Mar; 296(12):684-5. PubMed ID: 190538
    [No Abstract]   [Full Text] [Related]  

  • 8. Effects of angiotensin-converting enzyme inhibitors on the vascular response to norepinephrine.
    Saruta T; Suzuki H; Okuno T; Kondo K
    Am J Cardiol; 1982 Apr; 49(6):1535-6. PubMed ID: 6176110
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Effect of SQ-20881, an inhibitor of carboxycathepsin (angiotensin I-converting enzyme), on peripheral circulation during the early postresuscitation period].
    Orekhovich VN; Eliseeva IuE; Pavlikhina LV; Negovskiĭ VA; Novoderzhkina IS
    Dokl Akad Nauk SSSR; 1980; 250(1):253-6. PubMed ID: 6155247
    [No Abstract]   [Full Text] [Related]  

  • 10. [From teprotide to captopril. Rational design of ACE inhibitors].
    Nemec K; Schubert-Zsilavecz M
    Pharm Unserer Zeit; 2003; 32(1):11-6. PubMed ID: 12577755
    [No Abstract]   [Full Text] [Related]  

  • 11. A comparison of the activity of the angiotensin converting enzyme inhibitors SQ 14 225, SA 446, and MK 421.
    Takata Y; Di Nicolantonio R; Mendelsohn FA; Hutchinson JS; Doyle AE
    Clin Exp Pharmacol Physiol; 1983; 10(2):131-45. PubMed ID: 6307563
    [No Abstract]   [Full Text] [Related]  

  • 12. [Isolation of carboxycathepsin (peptidyl dipeptidases 3.4.15.1) from bovine kidneys].
    Eliseeva IuE; Pavlikhina LV; Orekhovich VN
    Dokl Akad Nauk SSSR; 1974 Aug; 217(4):953-6. PubMed ID: 4368167
    [No Abstract]   [Full Text] [Related]  

  • 13. Vasoactive peptides and hypertension: role of angiotensin converting enzyme.
    Johnston CI; Iansek R; Millar JA; McGrath BP; Matthews PG
    Aust N Z J Med; 1981; 11(Suppl 1):59-63. PubMed ID: 6266379
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Development of specific inhibitors of angiotensin I converting enzyme (kininase II).
    Cushman DW; Cheung HS; Sabo EF; Rubin B; Ondetti MA
    Fed Proc; 1979 Dec; 38(13):2778-82. PubMed ID: 228989
    [No Abstract]   [Full Text] [Related]  

  • 15. Effect of chronic captopril treatment on circulating and tissue renin-angiotensin system in SHR rats.
    Hu WY; Chen DG; Chen SC; Jin XQ; Wang HJ
    Zhongguo Yao Li Xue Bao; 1996 Nov; 17(6):507-12. PubMed ID: 9863143
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A new potent inhibitor of converting enzyme: (2R,4R)-2-(2-hydroxyphenyl)-3-(3-mercaptopropionyl)-4-thiazolidinecarboxylic acid(SA446).
    Iso T; Yamauchi H; Suda H; Nakata K; Nishimura K; Iwao J
    Jpn J Pharmacol; 1981 Dec; 31(6):875-82. PubMed ID: 6174764
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Endocrine mechanisms in the pathogenesis of essential hypertension. VI. Blockade of the renin-angiotensin system as a therapeutical basis.
    Păuşescu E
    Physiologie; 1982; 19(4):245-64. PubMed ID: 6185963
    [No Abstract]   [Full Text] [Related]  

  • 18. Effects of neutral endopeptidase inhibition and combined angiotensin converting enzyme and neutral endopeptidase inhibition on angiotensin and bradykinin peptides in rats.
    Campbell DJ; Anastasopoulos F; Duncan AM; James GM; Kladis A; Briscoe TA
    J Pharmacol Exp Ther; 1998 Nov; 287(2):567-77. PubMed ID: 9808682
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Zinc, angiotensin I-converting enzyme and hypertension.
    Lockett CJ; Reyes AJ; Leary WP; Alcocer L; Olhaberry JV
    S Afr Med J; 1983 Dec; 64(26):1022-4. PubMed ID: 6316570
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Conversion of angiotensin I to angiotensin II.
    Erdös EG
    Am J Med; 1976 May; 60(6):749-59. PubMed ID: 190881
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.